Dermatology Research and Practice / 2018 / Article / Tab 2 / Research Article
Clinical Features and Treatment Outcomes among Children with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 20-Year Study in a Tertiary Referral Hospital Table 2 Clinical features of patients with Stevens-Johnson syndrome and overlap-toxic epidermal necrolysis.
SJS, N = 20 Overlap-TEN, N = 16 Overall, N = 36 P valueProdromal symptoms , N (%)15 (75.0) 11 (68.8) 26 (72.2) 0.677 Fever 14 (70.0) 11 (68.8) 25 (69.4) 0.352 Stinging eye 4 (20.0) 4 (25.0) 8 (22.2) 0.477 Sore throat 5 (25.0) 1 (6.2) 6 (16.7) 0.274 Cutaneous findings at the presentation , N (%) Morbilliform rash 19 (95.0) 11 (68.8) 30 (83.3) 0.036 Blister 5 (25.0) 9 (56.3) 14 (38.9) 0.056 Targetoid lesions 6 (30.0) 3 (18.8) 9 (25.0) 0.439 Purpuric macules 1 (5.0) 0 1 (2.8) 0.364 Mucosal involvement , N (%) Oral 19 (95.0) 16 (100.0) 35 (97.2) 0.364 Eye 17 (85.0) 13 (81.2) 30 (83.3) 0.764 Genital 15 (75.0) 11 (68.8) 26 (72.2) 0.677 Anus 3 (15.0) 3 (18.8) 6 (16.7) 0.764 Associated abnormalities GI abnormalities 9 (45.0) 9 (56.3) 18 (50.0) 0.502 Transaminitis 9 (45.0) 9 (56.3) 18 (50.0) 0.645 Direct hyperbilirubinemia 3 (15.0) 0 3 (8.3) 0.106 Electrolyte abnormalities 8 (40.0) 8 (50.0) 13 (44.4) 0.568 Hyponatremia 5 (25.0) 3 (18.8) 8 (22.2) 0.654 Hypokalemia 3 (15.0) 4 (25.0) 7 (19.4) 0.451 Hypocalcemia, hypophosphatemia 0 1 (6.2) 1 (2.8) 0.257 Renal abnormalities 1 (5.0) 1 (6.2) 2 (5.6) 0.359 Rising creatinine 1 (5.0) 0 1 (2.8) 0.364 Rising creatinine and hematuria 0 1 (6.2) 1 (2.8) 0.257
Significant values are shown in bold.